JP2024125139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024125139A5 JP2024125139A5 JP2023083308A JP2023083308A JP2024125139A5 JP 2024125139 A5 JP2024125139 A5 JP 2024125139A5 JP 2023083308 A JP2023083308 A JP 2023083308A JP 2023083308 A JP2023083308 A JP 2023083308A JP 2024125139 A5 JP2024125139 A5 JP 2024125139A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- egfr
- group
- cancer
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310201580.X | 2023-03-03 | ||
| CN202310201580.XA CN116212030A (zh) | 2023-03-03 | 2023-03-03 | 包含阿兹夫定的抗肿瘤药物组合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024125139A JP2024125139A (ja) | 2024-09-13 |
| JP2024125139A5 true JP2024125139A5 (https=) | 2025-03-31 |
| JP7783217B2 JP7783217B2 (ja) | 2025-12-09 |
Family
ID=86468723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083308A Active JP7783217B2 (ja) | 2023-03-03 | 2023-05-19 | アズブジンを含む抗腫瘍医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11878028B1 (https=) |
| EP (1) | EP4424310B1 (https=) |
| JP (1) | JP7783217B2 (https=) |
| KR (1) | KR20250166964A (https=) |
| CN (1) | CN116212030A (https=) |
| TW (1) | TW202435855A (https=) |
| WO (1) | WO2024183644A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116212030A (zh) * | 2023-03-03 | 2023-06-06 | 河南真实生物科技有限公司 | 包含阿兹夫定的抗肿瘤药物组合物 |
| CN116196325A (zh) * | 2023-03-10 | 2023-06-02 | 河南真实生物科技有限公司 | 包含阿兹夫定的免疫调节剂组合物 |
| CN121891392A (zh) * | 2024-10-18 | 2026-04-21 | 河南真实生物科技有限公司 | 阿兹夫定类药物的制药用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006081985A1 (en) * | 2005-02-04 | 2006-08-10 | F. Hoffmann-La Roche Ag | Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor |
| CN102000103B (zh) * | 2009-12-21 | 2011-12-21 | 郑州大学 | 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用 |
| CN108721242B (zh) * | 2015-06-03 | 2021-03-02 | 南京三迭纪医药科技有限公司 | 药品剂型及其使用 |
| CA3021021A1 (en) * | 2016-04-15 | 2017-10-19 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors |
| TWI818007B (zh) * | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US20210196719A1 (en) * | 2018-05-23 | 2021-07-01 | Jiangsu Hengrui Medicine Co., Ltd. | Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseases |
| CN110003183A (zh) * | 2019-04-09 | 2019-07-12 | 河南真实生物科技有限公司 | 2-（2，4，5-取代苯氨基）嘧啶衍生物及其晶形b |
| WO2020206603A1 (zh) | 2019-04-09 | 2020-10-15 | 河南真实生物科技有限公司 | 2-(2，4，5-取代苯氨基)嘧啶衍生物及其晶形b |
| WO2021148396A1 (en) * | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN114191558A (zh) * | 2020-09-17 | 2022-03-18 | 上海翰森生物医药科技有限公司 | Egfr抑制剂与抗血管新生药物在治疗肿瘤疾病的药物中的用途 |
| CN114569728B (zh) * | 2020-11-30 | 2023-11-28 | 诺未科技（北京）有限公司 | 一种组合物及其应用和药物 |
| CN115006397A (zh) * | 2021-03-05 | 2022-09-06 | 上海翰森生物医药科技有限公司 | 一种预防或治疗肿瘤疾病的药物用途 |
| CN116212030A (zh) * | 2023-03-03 | 2023-06-06 | 河南真实生物科技有限公司 | 包含阿兹夫定的抗肿瘤药物组合物 |
-
2023
- 2023-03-03 CN CN202310201580.XA patent/CN116212030A/zh active Pending
- 2023-05-19 EP EP23174301.4A patent/EP4424310B1/en active Active
- 2023-05-19 JP JP2023083308A patent/JP7783217B2/ja active Active
- 2023-05-19 US US18/199,402 patent/US11878028B1/en active Active
-
2024
- 2024-03-01 KR KR1020257033469A patent/KR20250166964A/ko active Pending
- 2024-03-01 TW TW113107353A patent/TW202435855A/zh unknown
- 2024-03-01 WO PCT/CN2024/079625 patent/WO2024183644A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024125139A5 (https=) | ||
| EP4161511B1 (en) | Novel small molecules for targeted degradation of untargetable kras in cancer therapy | |
| Hoang et al. | Oncogenic signaling of MEK5-ERK5 | |
| Mishra et al. | Genomic alterations of ERBB receptors in cancer: clinical implications | |
| JP7085985B2 (ja) | 悪性腫瘍治療用製剤及び組成物 | |
| CN115244058A (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| JP5852678B2 (ja) | 抗腫瘍剤の効果増強剤 | |
| JP2014533284A5 (https=) | ||
| RU2016130986A (ru) | Ингибитор киназы и его применение | |
| JP5537035B2 (ja) | Ｃｄｋ阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ | |
| JP2014518544A5 (https=) | ||
| CA3184076A1 (en) | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer | |
| JPWO2021060453A5 (https=) | ||
| JPWO2020032105A5 (https=) | ||
| IL319292A (en) | Cytotoxic imidazo[2,1-A]pyridine compounds and their use in therapy | |
| CN111511745A (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2024125140A5 (https=) | ||
| WO2018021200A1 (ja) | Ｒｕｎｘ阻害剤 | |
| JP2022550040A5 (https=) | ||
| JP2022512874A5 (https=) | ||
| JP5683462B2 (ja) | オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ | |
| TWI916370B (zh) | 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子 | |
| JP2018526377A5 (https=) | ||
| La Franca | Design, synthesis and biological evaluation of new anticancer drugs: FGFR inhibitors | |
| Miao et al. | Design, synthesis and biological activity evaluation of a novel selective inhibitor in PLK1 with acyl or sulfonyl substituted dihydroindole structure |